Study Spotlight

Study Spotlight

Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.


Researchers compared treatment with orlistat plus l-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and inflammatory parameters in obese type 2 diabetic patients. The study enrolled 258 patients with uncontrolled type 2 diabetes mellitus (T2DM) who were randomized to take orlistat 120 mg three times a day plus l-carnitine 2 g one time a day or orlistat 120 mg three times a day. The following parameters were evaluated at baseline and after 3, 6, 9, and 12 months: body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (Tg), adiponectin (ADN), leptin, tumor necrosis factor-alpha (TNF-alpha), vaspin, and high-sensitivity C-reactive protein (Hs-CRP). Rese archers found better improvement in body weight, vaspin, inflammation, glycemic and lipid profile with orlistat plus l-carnitine compared to orlistat alone. These results suggest L-carnitine may be of benefit to diabetic patients.

Click Here to visit the journal website. Subscription required to view the full text of the article.

 

Socialize
Website by Webfitters